Advanced in Sphincter of Oddi Dysfunction

Dr. Olga Brawman-Mintzer

Psychiatry
171 Ashley Ave, 
Charleston, SC 
Advanced in Sphincter of Oddi Dysfunction
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical Research

Overview

Olga Brawman-Mintzer is a Psychiatrist in Charleston, South Carolina. Dr. Brawman-Mintzer is rated as an Advanced provider by MediFind in the treatment of Sphincter of Oddi Dysfunction. Her top areas of expertise are Sphincter of Oddi Dysfunction, Biliary Dyskinesia, Alzheimer's Disease, Dementia, and Gallbladder Removal.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Sphincter of Oddi Dysfunction.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in SC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Prazosin
Study Phase: Phase 2
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Device, Drug
Study Drugs: Aripiprazole, Venlafaxine XR
Study Phase: Phase 4
View 3 Less Clinical Trials

31 Total Publications

Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).
Journal: Journal of affective disorders
Published: March 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brawman-Mintzer's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile